OncologyCE
LECTURECME

Optimizing Multiple Myeloma Treatment Selection in Your Community Oncology Practice

Author(s)/Faculty: Robert M. Rifkin, MD, FACP
Release Date: 1/7/2019Expiration Date: 1/6/2020
Credit Type: CMENumber of Credits: 0.75
Content Type: LectureProvider:
The approval and integration of several novel therapeutic agents into the treatment of patients with multiple myeloma (MM) has led to improved clinical outcomes. With the enrichment of the therapeutic landscape for MM, challenges have arisen regarding the incorporation of these newer agents into existing treatment protocols, and with individualizing these treatment regimens for specific patients. As new therapeutic agents such as thalidomide derivatives, proteasome inhibitors, immunomodulators, and monoclonal antibodies are incorporated into doublet, triplet, and quadruplet combinations, the potential continues to further enhance outcomes in patients with MM. Within this education activity, an expert in the field will review the latest clinical evidence regarding emerging combinations for newly diagnosed, transplant-ineligible MM, as well as provide guidance for the individualization of treatment protocols for patients with relapsed/refractory MM.